Abstract
Actionable mutation testing for ALK, ROS1, BRAF and EGFR in lung adenocarcinoma is currently recommended as standard practice. In this study we calculated the prevalence rates of these mutations in lung adenocarcinoma diagnosed at SEALS Kogarah, St George Hospital between May 2020 and October 2021. There were 158 non-small cell lung cancer (NSCLC) specimens diagnosed and 121 eligible adenocarcinoma specimens were included in the study. Our analysis showed mutation prevalence for ALK of 3.3%, ROS1 1.7%, EGFR 26.4% and BRAF 0%.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
